Carisma Therapeutics, Inc.

NasdaqGM:CARM 주식 보고서

시가총액: US$42.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Carisma Therapeutics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Steve Kelly

최고 경영자

US$3.5m

총 보상

CEO 급여 비율13.2%
CEO 임기1.5yrs
CEO 소유권n/a
경영진 평균 재임 기간1.4yrs
이사회 평균 재임 기간1.5yrs

최근 관리 업데이트

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

CEO 보상 분석

Steve Kelly 의 보수는 Carisma Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$461k

-US$87m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$80m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$666kUS$440k

-US$61m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$1mUS$416k

-US$41m

보상 대 시장: Steve 의 총 보상 ($USD 3.50M )은 US 시장( $USD 679.79K ).

보상과 수익: 회사가 수익성이 없는 동안 Steve 의 보상이 증가했습니다.


CEO

Steve Kelly (59 yo)

1.5yrs

테뉴어

US$3,504,425

보상

Mr. Steven Kelly, also known as Steve, is President, Chief Executive Officer and Director of Carisma Therapeutics, Inc. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics...


리더십 팀

이름위치테뉴어보상소유권
Steven Kelly
President1.5yrsUS$3.50m데이터 없음
Michael Klichinsky
Co-Founder & Chief Scientific Officer1.5yrsUS$1.60m1.17%
$ 489.2k
Richard Morris
CFO, Chief Compliance Officer1.5yrsUS$1.66m0%
$ 0
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Eric Siegel
General Counsel & Corporate Secretary1.3yrs데이터 없음데이터 없음
Terry Shields
Senior Vice President of Human Resources1.3yrs데이터 없음데이터 없음
Tom Wilton
Chief Business Officer4.7yrs데이터 없음데이터 없음
Eugene Kennedy
Chief Medical Officerless than a year데이터 없음데이터 없음
Kenneth Locke
Senior Vice President of Technical Operationsless than a year데이터 없음데이터 없음

1.4yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: CARM 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Steven Kelly
President1.5yrsUS$3.50m데이터 없음
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Sanford Zweifach
Independent Chairman of the Board1.5yrsUS$271.55k0.00099%
$ 415.4
Hyam Levitsky
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Nina Bhardwaj
Member of Scientific Advisory Board4.2yrs데이터 없음데이터 없음
Briggs W. Morrison
Independent Director1.5yrsUS$220.20k0.029%
$ 12.3k
Marella Thorell
Directorless than a year데이터 없음데이터 없음
Michael Torok
Independent Director1.5yrsUS$207.95k0.24%
$ 102.3k
John Hohneker
Independent Directorless than a year데이터 없음0%
$ 0
Lisa Coussens
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Prasad Adusumilli
Member of Scientific Advisory Board4.2yrs데이터 없음데이터 없음
Lin Guey
Member of Scientific Advisory Board1.6yrs데이터 없음데이터 없음

1.5yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: CARM 의 이사회경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.